function. For example, when mice were primed with avirulent ectromelia (ECTV) intraperitonally, and later 71 challenged with virulent ECTV only antibody was necessary (51, 52) . Experiments done with Dryvax s.s. 72 vaccinated Rhesus macaques have also shown a necessity for antibodies by showing protection from lethal 73 MPXV challenge required the presence of B cells (22) , and that passive treatment with vaccinia immune 74 globulin (VIG) was sufficient to prevent death. Thus, interest in understanding in greater detail the 75 requirements for protection, and the protective components of the humoral response remain. 76
Most of the protective antigens for OPV infection that have been studied are surface proteins from the 77 two primary virion forms, the intracellular mature virions (MV) and extracellular enveloped virions (EV). 78
These immune response targets include MV proteins L1, A17, A27, D8 H3, A13, A28; and EV proteins A33 79 and B5 (15, 24, 28, 31, 40, 62, 67, 70) . The protective nature of antibodies reactive to these MV proteins, 80 especially when combined with those towards EV, indicate the possibility that a select subset of proteins may be 81 sufficient to provide protective immunity. However, protein targets of humoral immunity upon vaccination are 82 known to differ between individuals (5) and many viral proteins have not been implicated in protective 83 responses despite being effective at eliciting host immune induction (15, 16, 19, 60) . Furthermore, recent 84
analysis of CD8 T cell responses in mice have indicated that larger than expected MHC dependent differences 85 were seen between VACV infected outbred and inbred populations (23) which raises the question of whether 86 these observations are also true for B cell responses in an outbred model. The mechanism of protection may 87 include all of these factors (specific antigen recognition, cellular responses or diversity of neutralizing antibody 88 response), however, the need for a better understanding of the mechanisms of protection in newly developed 89 smallpox vaccines will be crucial for understanding novel vaccine efficacy. 90
We present research to further explore components of vaccine and OPV challenge induced immunity in 91 the prairie dog model of OPV infection that emulates human systemic OPV infections. However, it is important 92 to show that vaccination of prairie dogs induces a similar immune response, and not just similar levels of 93 response relative to humans. Thus, we utilize antigenic profiling to assess similarities and differences. Our 94 results add value to the use of this model of systemic OPV vaccination and infection, as well as may be utilized 95 to better understand the humoral correlates of protection in human vaccination against smallpox. Protein 96 appropriate PPE. The vaccinees, aged 23-34 and 25-30, were vaccinated with Dryvax or ACAM2000, 149 respectively. Sera were collected prior to vaccination and approximately at 7 day intervals afterwards, from day 150 7 to day 49 post vaccination. Vaccinia Immune Globulin Intravenous (VIGIV) was received from the Strategic 151 National Stockpile, (CDC, Atlanta, GA, USA) and was produced by Cangene (Cangene Corporoation, 152 Winnipeg, CA). It is an anion-exchange column purified globulin fraction from VACV (Dryvax) vaccinated 153 and boosted plasma donors (8). Lot 1730203 used herein had total protein (IgG) of 55 mg/ml. 154 155
Enzyme-Linked Immunosorbant Assays (ELISA). A modified version of the ELISA was used for analysis 156
of Prairie dog anti-OPV (Keckler et al, 2011, in press ). Briefly, microtiter plates (Immulon II; Dynatech) were 157 coated with crude VACV or BSC-40 cell lysate by overnight incubation and subsequently inactivated, blocked, 158
and washed prior to incubation with dilutions of prairie dog sera then ImmunoPure A/G-HRP conjugate 159 (Pierce). The BSC-40 cell lysate half of each plate was used to generate a cut-off value (COV) for each plate by 160 averaging all the values of the BSC-40 lysate half and adding two standard deviations (SD). Specimens were 161 considered positive if the test sample's value was above the COV. The endpoint titer for each animal was 162 determined based on the highest dilution that was positive. Study 1 animals were used for time course analysis 163 of ELISA and microarray signals. ELISA of human samples was performed as previously described (37). 164
Briefly, crude VACV was coated onto microtiter plates overnight, inactivated, blocked, and washed prior to 165 incubation with human sera then goat anti-human IgG-HRP (KPL, Gaithersburg, MD). After development, a 166 COV was determined using the mean OD from known naïve standards plus 3 SD. Sera were considered 167 positive if the test sample's value was above the COV. The endpoint titer was determined based on the highest 168 dilution that was positive. For comparison with microarray fluorescence, reciprocal values (log transformed) 169 are used. 170 171 HCS-GFP neutralization assay. Neutralizing antibody titers (NAb) post vaccination were measured using the 172 ArrayScan high-content screening (HCS) reader to detect green fluorescent protein (GFP) introduced by 173 infection with a GFP expressing VACV-WR strain virus (36). This assay detects the percentage of GFP 174 producing cells, which is then normalized to control wells to obtain a relative percent responder (RPR) value. 175
Reported 50% RPR values correlate with the serum inhibitory concentration required to neutralize 50% of viral 176 infection (ID50) in a traditional plaque reduction neutralization titer (PRNT) assay. 177
178
Array Probing and Signal Calculation. Sera were probed on the arrays at 1:100 dilution in protein array 179 blocking buffer (Whatman) plus 20% E. coli lysate to block antibodies reactive toward E. coli proteins present 180 in the transcription/translation mixture. Remaining steps were carried out in blocking buffer with 10% E. coli 181 lysate. VIG was probed on the arrays at 1:500 dilution. For human sera and VIG, a secondary Donkey anti-182
Human IgG -Biotin conjugate (Jackson Immuno) at 1:200 was used followed by a Streptavidin -Surelight P-3 183 (Columbia Biosciences) conjugate. Prairie dog serum antibodies were visualized using Protein G -Biotin 184 Wilcoxon rank test is a non-parametric test to compare related samples and determine if their population mean 217 ranks are different; it was utilized given the variability found in some array responses. Data were compiled by 218 identifying microarray fluorescent values above the appropriate cutoff value (150 or 1000) but did not include 219 the 2-fold rise in reactivity otherwise utilized in order to allow comparison of naïve samples. 220
221

Results
222
Vaccine induced humoral immunity. We first set out to provide a global view of reactivity and identify major 223 trends between days 21-49 after vaccination of a group of human subjects and prairie dogs. A core group of 224 antigens elicit antibodies following vaccination with Dryvax and ACAM2000 in both species, as well as 225 IMVAMUNE vaccinated prairie dogs (Fig. 1) . As standards for immune reactivity on the array, naïve sera was 226
Interrogation with VIG revealed immune recognition of 26 of 62 antigens (Fig. 1) . The highest reactivity as 228 measured by fluorescence intensity on this array, was observed to MV proteins WR148, A13, H3, D8, and A27; 229 EV protein A56; core proteins I1, A10; and H6 and D13 (other function). As a group, MV and core proteins 230 were most frequently recognized by VIG (Fig. 1) . In comparing vaccine induced immunity in human and 231 prairie dogs regardless of vaccine strain, commonly reactive antigens, defined as having greater than 50% 232 reactivity within a vaccination group, were observed in both host species and include WR148, A13, H3, D8, I1 233 and D13. Prominent differences observed include absence of a response to MV protein A17 in prairie dogs, but 234 also more frequent recognition of MV protein A9, EV protein A56, Evasion protein E3 and WR169 (unknown 235 function) (Fig. 1 , indicated by *, and Table 2 ). Similar to the VIG profile, MV proteins account for the majority 236 of reactive proteins in vaccinees and accounted for 44% of total signal. Within individual serum samples, one 237 or more EV proteins were frequently recognized in each vaccine groups, but rarely was the same protein 238 commonly recognized. One exception was reactivity to A56 in prairie dog Dryvax and ACAM2000 vaccinees 239 but not those receiving IMVAMUNE. Reactivity was also predominantly absent to EV protein F13 in all 240 groups. Responses to core proteins and enzymes accounted for 22% of chip signal. Host immune evasion and 241 virulence factor recognition was absent in human vaccines and seen only minimally in prairie dogs, with a 242 predominance of reactivity to E3 in the Dryvax group. Overall, an average reactivity to 8.5 of 62 antigens was 243 found in both humans and prairie dogs. Additionally, while there were many commonly reactive antigens, no 244 antigen was reactive in 100% of all human and prairie dog vaccinees. 245 246 Human response to vaccination. We then established a baseline for comparison by examining human antibody 247 profiles after Dryvax and ACAM2000 vaccination. Responses between vaccine strains were highly similar 248 ( Fig. 1 and Table 2 ) and included recognition of MV proteins WR148, A13, H3, D8, and A17 and to a lesser 249 extent A27L. EV proteins A56, B5, A33, A36 and A34 were recognized by at least one Dryvax or ACAM2000 250 vaccinated individual, and A33 was recognized by more than 50% of ACAM2000 vaccinees. Human responses 251 were observed to core proteins I1L, A10, and A4 in Dryvax and ACAM2000 vaccinees, while responses to 252 proteins categorized as other/unknown function included D13 and A11. Ranked mean fluorescent intensities by 253 proteins with positive hits reveal that WR148 was the most immunogenic protein in human vaccinees, followed 254 by A13, then I1 and D13 for both Dryvax and ACAM2000 vaccines (Fig. 1) . 255
256
Prairie Dog response to vaccination. We then set out to examine prairie dog response in detail and to assess 257 similarities and differences between species. When given Dryvax and ACAM2000, prairie dogs showed highly 258 similar responses to human vaccine responses ( Fig. 1 and Table 2 ). Of animals vaccinated with Dryvax and 259 ACAM2000, 70% reacted to MV proteins WR148, H3, and D8, and 45% reacted to each of those plus A13. In 260 contrast to humans, A13 responses were less frequently seen, with only a 56% response rate vs. 100% in 261
humans. A17 responses were also predominantly absent in prairie dog and EV protein A56 was commonly 262 recognized in Dryvax and ACAM2000 vaccinated animals. Core proteins I1L, A10L and A4L were also 263 recognized in both live vaccine groups at levels slightly higher than those seen in human. E3L (Evasion) 264 protein was found reactive in Dryvax vaccinated prairie dogs, though much less so in ACAM2000 (as in 265 humans). Similar to human responses, prairie dogs vaccinated with Dryvax or ACAM2000 react to scaffold 266 protein D13L and protein of unknown function WR169, but reactivity to morphogenesis protein All was absent 267 in ACAM2000. For prairie dogs vaccinated with IMVAMUNE, highly reactive proteins were significantly 268 more limited and include MV proteins A13L, H3L and D8. Except for one low level binding event (less than 2 269 times the cutoff), no response was observed to WR148, which is known to be deleted in IMVAMUNE. 270 IMVAMUNE also induced lower responses overall to EV proteins than that seen with Dryvax and ACAM2000 271 and comparable reaction was observed to core proteins I1L and A10L versus live vaccines. Overall, a 272 predominant absence of response in this assay to A17L was consistent in all vaccinated prairie dogs. Of 273 interest, evasion protein E3L was reactive almost exclusively in Dryvax immunized animals. Reactive proteins 274 in IMVAMUNE vaccinees was comparable to Acambis2000, and both had fewer recognized antigens than 275 Dryvax vaccinees. Ranked mean fluorescent intensities by proteins with positive hits reveal that WR148 276 (except in IMVAMUNE) and I1L were the most immunogenic proteins for prairie dogs (Fig. 1) . 277
Immune response to proteins targeted by neutralizing antibodies after vaccination. To more specifically 279
analyze antibody profiles related to neutralizing capacity, the reactivity of sera to known neutralizing targets 280 A13, A17, D8, H3, A27 and B5, and protective targets A33, A4 and A10 was evaluated (Fig. 2a) . Since 281 neutralizing capacity has been shown to be redundant (5), reactivity to these eight proteins was combined to 282 determine if a minimum number of recognition events was associated with a neutralizing titer. Neutralizing 283 target L1 was excluded from this array as it failed to be reactive when produced from this E. coli system (14), 284 and A28 (62), although included on the array, was excluded from this analysis as response was absent in all but 285 one vaccinee. In all groups, post vaccination data showed increased reaction to this subset of proteins. Higher 286 reactivity in pre-vaccination response for humans was due to background binding to A4. Additionally, since 287 prairie dog IMVAMUNE pre-vaccination sera were unavailable for testing, higher initial reactivity was due to 288 increased recognition of D8 following the first dosing of IMVAMUNE, which is presented herein as pre-289 vaccination. Lower overall response post-vaccination in prairie dogs was in part due to the absence of reactivity 290 to A17, an observation made in Fig. 1 . While humans responded strongly to A17 after live vaccination, prairie 291 dogs typically failed to mount a response to this protein following live or attenuated vaccination. No statistical 292 difference in the total number of responses was observed between human vaccinees and prairie dogs given 293 Dryvax or IMVAMUNE (p-values 0.56-1; Wilcoxon rank sum). However, the total number of known 294 neutralizing targets recognized in prairie dogs given ACAM2000 was statistically lower than Dryvax or 295 IMVAMUNE vaccinated animals (P=0.04 and 0.03, respectively; Wilcoxon rank sum). Sera were also 296 evaluated using the HCS-GFP neutralization assay (36) to observe neutralizing antibody (NAb) titer (Fig. 2b) . 297
Neutralization increased post vaccination with NAb titers (50% RPR titer) of 9.6 × 10 2 and 4.2 × 10 2 observed 298 in Dryvax and ACAM2000 vaccinated humans. Post-vaccination NAb titers for each prairie dog group was 3.4 299 ×10 2 , 1.9 × 10 2 , and 7.3 × 10 2 respectively. Insufficient pre-vaccination sera were available for prairie dog 300 vaccinees for HCS-GFP testing, however we recently showed that NAb titers of unvaccinated prairie dogs were 301 typically below 1. (Fig. 3) and aggregate results for all temporally analyzed vaccinees (Fig. 4)  313 shows correlation between the two assays. In observing individual responses (Fig. 3) , ELISA EPTs typically 314 rose by day 14 in both species. Human EPTs then showed modest increases in later time points, however 315 prairie dogs typically showed no further increases. In both species, the fluorescence response to individual 316 proteins on our array were predominantly below the cutoff initially and steadily increase at later time points. As 317 previously noted in Fig. 1, WR148 , A13, H3 and D8 were among the most antigenic proteins. Response to 318 A17 was seen in human but remained below the cutoff in prairie dog. To compare the microarray and ELISA 319 assays, results for all time points were combined and displayed graphically (Fig. 4) . Microarray fluorescence 320 with human samples was better correlated with the ELISA EPT than prairie dogs, although both species show 321 increases in fluorescence associated with higher titers. Human samples reached maximal ELISA titer of 10 3 , 322 whereas prairie dog sera, on average could be diluted to (Fig. 5 ). Among these were MV proteins WR148 (except in MVA 330 vaccinated animals), A13, H3 and D8; core proteins I1 and A10; and virion scaffold protein ('other') D13 331 (Table 3) . MPXV challenge also induced strong primary antibody response to proteins that were minimally or 332 not recognized after vaccination (Table 3 , underlined proteins), including MV proteins A17, A27, A26 and 333 A14; EV proteins A56, B5 and F13; core proteins A4, H5, and I3; enzymatic proteins L4, F2, H6 and E4; 334 immunomodulatory proteins E3, A46, C23 and B29; and virion assembly protein A11 (other) and WR169, 335 whose function is unknown. Of post-challenge commonly recognized antigens, four were rarely seen post-336 vaccination in prairie dogs and only minimally reactive to human VIG. Proteins F2 and A3 (core/enzyme) were 337 most unique as they were each reactive only once post vaccination, but recognized by 73% and 42% of 338 respective subjects once challenged (Fig. 5) . The immunomodulatory protein C23, and its gene duplicate B29 339 (evasion/virulence), were also unrecognized by VIG and initially recognized in only 8% and 13% of vaccinees 340
respectively, but were reactive in 50% and 55% of samples post-challenge. Three additional proteins also rarely 341 One concern when using non-clonal and unpurified proteins was the potential for background reactivity 362 due to aberrant protein production or the complexity of the crude mixture spotted. A high degree of correlation 363 between our results and others using quantified or purified protein arrays would indicate that this is not an issue. 364
In one of the more complete efforts to date, 193 of 273 Vaccinia Copenhagen strain open reading frames were 365 cloned, expressed, and purified baculovirus proteins and found that <10% of the proteome was reactive to VIG 366 or vaccinated individuals (60). Using a rabbit reticulocyte system, Duke-Cohan et al. (19), selected 25 surface 367 exposed or known antigenic proteins of the 218 ORFs of the WR proteome to produce proteins in a micro-368 ELISA format. Reactivity was found to 17 proteins, although only 10 were strongly reactive. The correlation 369 of vaccinated individuals and VIG profiles were similar between both sets of experiments. In our experiments, 370 13 proteins were recognized by more than one vaccinee and 26 proteins were recognized by VIG. Overall, 371 between all sets of results there was good concordance when looking at strongly reactive proteins such as D13, 372 H3, D8, I1, A33, A27, and B5. When comparing lesser reactive proteins, although there was variability as to 373 which individual proteins were recognized, our experimental method did not produce significantly different hits 374 than either the Schmid or Duke-Cohan data sets. A comparative table of reactivity observed each system is 375 found in supplemental Table S2 . 376
Our results show significant reactivity to membrane proteins in vaccinated humans and prairie dogs, 377 with WR148, A13, H3, D8, and A17 commonly seen. The latter four MV proteins have all been shown to be 378 effective targets for virus neutralization and thus critical targets of the immune system to inactivate and limit 379 virus spread (46). However, A17 was recognized less frequently in prairie dogs with only 6 of 34 animals 380 responding to it, and four of those from within the ACAM2000 group. A17 is a MV protein that is associated 381 on July 9, 2017 by guest http://jvi.asm.org/ Downloaded from with viral morphogenesis and is essential for replication (68). The N-terminal region has been identified as the 382 target of neutralizing antibodies as well as the region which interacts with A14 and A27 (44). As such, lessened 383 reactivity may be indicative of subtle changes that limit accessibility of the external N-terminus region, or this 384 region may simply be less-immunogenic in the prairie dog. A fifth MV neutralizing target, A27 was seen in 385 nearly 50% of Dryvax vaccinated individuals of both species, but failed to react with any ACAM2000 or 386 IMVAMUNE vaccinee. Protein L1 was excluded from the chip even though it has historically been shown to 387 produce neutralizing antibodies (59, 69) . At the time of printing, L1 failed to produce a response in human sera, 388 and was only minimally reactive concentrations higher than normal (data not shown). L1 is notable for 389 significant disulfide bonding thus the limitation is likely structural, and some gains have since been realized 390 (18). With baculovirus expression detection ranged from 0-30% recognition (46, 60), and in a rabbit 391 reticulocyte lysate expression system, recognition was less than <25%, although a strong correlation with 392 neutralization in 4 samples with anti-L1 antibodies was noted (19) . 393
There were fewer and more varied responses to EV proteins after vaccination regimens in both species 394 with serorecognition of A33, and sometimes B5 as indicated by low level but significant fluorescence intensity 395 in humans, and serorecognition of A56 and B5 in prairie dogs. Interestingly, upon MPXV challenge, prairie 396 dogs show near universal response to A56, B5 and to F13, and lower response to A34 and A36. This finding is 397 interesting since EV virions are thought to aid in virus dissemination in natural infection (53) and typical 398 vaccine strains produce only a single localized lesion. However, it is unclear whether this difference in 399 reactivity to EV proteins is due to limited spread from the vaccination site or simply due to less immunologic 400 insult than the systemic spread commonly found with monkeypox infection. It is also possible that since EV 401 proteins would likely be post-translationally modified, this low reactivity is an artifact of the E. coli system. 402
However, low frequency of reactivity after immunization to EV proteins was also noted in similar assays using 403 different expression systems (19, 60) . Reactivity to EV proteins using single antigen ELISA showed increases 404 in response after vaccination (54) Antibody response to core proteins after vaccination was highly similar between virus strains and 412 species. As core proteins, accessibility of each of these would be limited until lysis of infected cells and then 413 would expected to be somewhat correlated to their relative abundance and availability of immunogenic 414 epitopes. Reports of relative abundance in MV virions (11, 56) show that A4 and A10 were predominant 415 proteins, with I1 encompassing as little as 1/100 their respective total mass. This relationship of antigen mass to 416 antibody recognition was reversed here as I1 was immunodominant. 417
The recognition of E3 by Dryvax vaccinated prairie dogs, but not in humans was also interesting. This 418 protein was recognized only weakly in one human vaccinee, and was previously seen with equivocal 419 recognition by humans and no recognition by primate vaccinees (17, 41). By comparison, strong recognition of 420 E3 is seen in mice and rabbits given pathogenic VACV WR strain (14, 16) and primates challenged with 421 MPXV show reactivity to E3, and in particular the truncated MPXV homologue of E3 (41). Similar to the 422 absence of reactivity to A17, reactivity to E3 after vaccination may result from species specific sensitivity to 423 available epitopes, and only upon challenge (VACV WR or MPXV) is the response sufficient to ensure 424 measureable response. It is also possible that stronger recognition is at least partially a function of the 425 pathogenicity of challenge virus or the degree of systemic spread of virus during disease. 426
There were three commonly recognized proteins after vaccination that did not fit into one of our 427 aforementioned groups. D13 is a scaffold protein that is lost prior to MV maturation (63). However, its 428 necessity as a structural protein in crescent formation and ubiquity confirm it as a likely immunologic target. 429 A11 is a non-structural protein also associated with crescent formation (13). Its near absence in ACAM2000 430 vaccinated prairie dogs was somewhat surprising, but upon examination of signal intensities may simply be a 431 function of low levels of response and thus was indistinguishable from background. While A11 was recognized 432 on July 9, 2017 by guest http://jvi.asm.org/ in all other vaccination groups, it typically had an average intensity of only 2 to 3 times the cutoff value, and for 433 all groups was in the bottom third of reactive proteins by ranked average intensity. 434
Consistent with previous reports of vaccine immunogenicity (27), we saw no difference between Dryvax 435 and ACAM2000 array responses in humans, with an average of 10.0 and 9.3 array hits per sample respectively. 436
However, in prairie dogs there was a trend of lower response after ACAM2000 vaccination relative to that of 437 Dryvax, including many instances where Dryvax vaccinees responded to a given protein 100% of the time 438 whereas ACAM2000 vaccinees were less frequently recognized, but still greater than the 50% designation 439 shown in Table 2 . A similar overall reduction was observed after IMVAMUNE vaccination as well, but only 440 part of which can be accounted for in the loss of reactivity to WR148. Relative to Dryvax, reduced antibody 441 response has also been seen in IMVAMUNE vaccination of humans (29) and included absent or reduced 442 reactivity to WR148 and A17, but also significantly lower response to A56, A27 and A33. We observed no 443 reactivity to each of these antigenic targets in IMVAMUNE vaccinated prairie dogs as well. The lower overall 444 response between viruses resulted in a drop in the number of recognized antigens from an average of 11.7 hits 445 per sample after Dryvax vs. 7.8 and 7.9 hits per sample after ACAM2000 or IMVAMUNE. This difference 446 accounts for ~15% loss in positive hits over the entire proteome between the vaccines. ELISA geometric mean 447 titers also showed this reduced response, with both ACAM2000 and IMVAMUNE having between 2-10 fold 448 reduced peak GMTs relative to Dryvax. 449
After MPXV challenge, the response to a much greater number of antigens (n=27.4) than after 450 vaccination (n=9.1) may reflect the more systemic presentation of the virus. In Dryvax revaccination cases only 451 a modest increase in number of recognized targets has been seen (16). We also recently showed that disease 452 antigens recognized by proteome analysis and disease severity upon challenge of the vaccinated animals. 476
Prairie dogs given IMVAMUNE responded to fewer antigens by our analysis and showed some signs of 477 morbidity upon challenge (42). No morbidity was observed when challenging Dryvax vaccinated animals. 478
Although there were fewer targets overall, there was no consistently absent antibody target that correlated with 479 protective or known neutralizing targets, nor were there statistically significant differences in the average 480 number of neutralizing targets recognized. However, we also saw fewer responses during ACAM2000 481
vaccination, yet no increase in morbidity after challenge, suggesting that multiple factors are involved in 482 immunogenicity and protection. It would also be of interest to gain a greater insight into the full spectrum of 483 antibody response before and after challenge using a MPXV proteomic approach. Keasey et al. (2011) 484 on July 9, 2017 by guest http://jvi.asm.org/ Downloaded from observed greater increases in antibody response to several MPXV proteins relative to VACV proteins by 485 aerosol MPXV challenged macaques (41) indicating that although broad cross-reactivity exists, a stronger 486 response may be directed towards MPXV specific proteins. Differences in neutralization titer have also been 487 observed depending on the strain of OPV utilized in the PRNT assays (30, 32) . While a direct comparison 488 between titration methods is not possible using the vaccinia-based HCS-GFP assay, future experiments that 489 shed light on the virus specificity of this broader response and the virus specific neutralization capacity after 490 vaccination and challenge would be of interest. 491
In conclusion, we have shown that antibody response in prairie dogs vaccination closely resembles that 492 of human vaccination when examined at the whole proteome level. While some differences were observed, 493 including variability in the recognition of proteins A17, A9, A56, E3 and WR169 after vaccination, there 494 remained a clear set of proteins recognized by all vaccinees in both species. Of proteins known to be targeted 495 by neutralizing antibodies, only the absence of A17 recognition in prairie dogs was observed. However, there 496 was no significant difference in neutralizing capacity, as demonstrated by similar 50% RPR titers in our HSC-497 GFP assay, suggesting this loss of reactivity alone is not critical in protection, nor is it a salient difference in the 498 animal model system. We observed fewer responses after vaccination with the attenuated IMVAMUNE strain, 499 which correlated with increased in morbidity when those prairie dogs were challenged with MPXV. We have 500 also shown that challenge with pathogenic MPXV induced a larger magnitude response to a greater number of 501 targets than vaccination, regardless of pre-challenge status (i.e., vaccinated or naïve). This dramatic increase in 502 frequency of antigen recognition after challenge may be relevant as safer, and likely more attenuated, vaccines 503 are developed. The increase in breadth of response after challenge also supports observations of lifelong 504 immunity following smallpox, but allows for the wide variations in waning immunity years after vaccination 505 (26, 38 
